Published on
March 26, 2025

In the media

BiotechTV interviews Peter Joyce (CEO & Co-founder)

About Greywolf Therapeutics

Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology to guide the immune system. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. We are progressing first-in-class antigen modulators to treat people living with cancers, autoimmune disorders, and infectious diseases.

Greywolf is headquartered in Oxford, UK.

More information: Website | LinkedIn

Media enquiries

Patrick White, Head of Communications

+44 (0)1235 644 970

patrick.white@gwt.bio

Discover how our therapies are reshaping treatment for various diseases and conditions.

Harnessing antigen modulation to empower T cells against diseases.